Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06646185

Improving Menstrual and VAginal Health for All

A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, participants will adopt each menstrual product for 2 menstrual cycles. Participants will provide vaginal microbiome samples via self-sample swabs at 3 points during each menstrual cycle. Given the crossover design of the study, there is not a dedicated control group.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Centre de Recherche sur les Maladies Emergentes et Re-Emergentes, Yaoundé, Cameroon

Loading trial locations.

About this study

In three countries, the investigators will follow a randomized crossover design to study the effects of menstrual products on the vaginal microbiome composition and diversity. Eligible participants who are willing to adopt pads, tampons and menstrual cups to manage their menstruation, and for which baseline composition of their vaginal microbiomes is determined through DNA sequencing of the 16s rRNA gene will enter a three-period crossover trial. Each period of the trial will consist of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of six different exposure sequences of menstrual products, as follows:

i) Tampon, Cup, Pad ii) Tampon, Pad, Cup iii) Cup, Tampon, Pad iv) Cup, Pad, Tampon v) Pad, Tampon, Cup vi) Pad, Cup, Tampon

In group "i)", participants will adopt tampons during the first two menstrual cycles (first period of the trial), followed by the adoption of cups during the next two menstrual cycles (second period), and lastly menstrual pads for the next two menstrual cycles (third crossover period). In groups ii) to vi) following the same design but in different sequences. Self-sampling kits will be provided during six consecutive menstrual cycles, a few days before the start of menses. Each kit will contain swabs for three self-sampling points during the menstrual cycle and the corresponding menstrual products.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • able to provide informed consent;
  • aged 18-35;
  • residing in the recruitment region and expecting to reside in the same region for at least six months following recruitment (Yaoundé/ Gounougou, Cameroon; Loreto/Lima/Maynas provinces, Peru; or Basel-Landschaft and Basel-Stadt cantons, Switzerland);
  • are native speakers or are able to read and understand one of the following languages in each respective country (German, French, Italian, English or Spanish in Switzerland; French or English in Cameroon; Spanish in Peru);
  • had menstrual cycles of 21-35 days for at least the last 4 months;
  • had menses which lasted at least 3 days for at least the last 4 months.

Exclusion criteria

  • experienced a menstrual abnormality with any of the menstrual cycles in the last 4 months (such as oligomenorrhea or amenorrhea, or bleed more than 7 days a month);
  • are pregnant or actively trying to become pregnant;
  • are breastfeeding;
  • used antibiotics and/or vaginal antifungals in the last 30 days prior to recruitment;
  • had a vaginal birth in the last 6 months;
  • vaginal surgery, perineal surgery, uterine surgery, miscarriage or abortion in the last 6 months;
  • history of Toxic Shock Syndrome ;
  • positive to detection of the toxic shock syndrome toxin-1 gen (tst) using Polymerase Chain Reaction (PCR);
  • Intrauterine device in situ;
  • under medication (treatment against infectious or chronic disease) at the time of recruitment or during the 3 weeks prior to recruitment;
  • clinical symptoms of vaginal infection;
  • smoker.

Treatment and study plan

Menstrual Pads

Other

Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Menstrual Cups

Other

Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Tampons

Other

Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Primary outcomes

  1. Log-ratio of Dialister to Lactobacillus crispatus relative abundances in vaginal swabs (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The abundances of each bacterial taxa are estimated from the DNA amplification and sequencing of amplicons from the 16S rRNA gene.

Secondary outcomes

  1. Log-ratio of Bifidobacterium vaginalis to Lactobacillus relative abundances in vaginal swabs (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The abundances of each bacterial taxa are estimated from the DNA amplification and sequencing of amplicons from the 16S rRNA gene.

  2. Log-ratio of Prevotella to Lactobacillus relative abundances in vaginal swabs (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The abundances of each bacterial taxa are estimated from the DNA amplification and sequencing of amplicons from the 16S rRNA gene.

  3. Dominant taxon in vaginal swabs (categorical variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The dominant taxon in a vaginal swab is defined as the most abundant taxon found with a relative abundance of at least 30% of the total bacterial DNA sequences found in the sample.

  4. Community state type in vaginal swabs (categorical variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The community state type in a vaginal swab is defined using the VALENCIA algorithm as described in this article: France, M.T., Ma, B., Gajer, P. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 8, 166 (2020). https://doi.org/10.1186/s40168-020-00934-6

  5. Total bacterial load in vaginal swabs (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    Indirectly estimated with qPCR of the 16S rRNA gene

  6. Self-reported vaginal complaints (discrete variable)

    Time frame: Monthly, from enrollment until study completion, an average of 6 months.

    Self-reported through follow up surveys along the six-month trial

  7. Vaginal pH (ordinal variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    Measured with a vaginal swab and a fixed indicator (3.6 - 6.1), just after menstruation ends.

  8. Alpha diversity (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    Alpha diversity indices (e.g., Shannon, Simpson) are estimated for each vaginal swab sample to quantify microbial richness and evenness.

  9. Log-ratio of Gardnerella module to L. crispatus module relative abundances (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The abundances of each bacterial module are estimated from the DNA amplification and sequencing of amplicons from the 16S rRNA gene.

  10. Log-ratio of Prevotella module to L. crispatus module relative abundances (continuous variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The abundances of each bacterial module are estimated from the DNA amplification and sequencing of amplicons from the 16S rRNA gene.

  11. molBV score (discrete variable)

    Time frame: Monthly, after menstruation ends, through study completion, an average of 6 months.

    The molBV score in a vaginal swab is defined and derived as described in this article: Usyk, M., Schlecht, N.F., Pickering, S. et al. molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nat Commun 13, 233 (2022). https://doi.org/10.1038/s41467-021-27628-3.

Study contacts

Contact information is provided by the study sponsor or research team.

Monica Ticlla, PhD

CONTACT

[email protected]

0041-61-284-8387

Sonja Merten, MD MPH PhD

CONTACT

[email protected]

0041-61-284-8387

Sponsors and collaborators

Lead sponsor

Swiss Tropical & Public Health Institute

Other

Collaborators

  • Centre de Recherche sur les Maladies Emergentes et Re-Emergentes
  • Universidad Nacional de la Amazonia Peruana
  • Universidad Peruana Cayetano Heredia
  • Universiteit Antwerpen

Registry information

Official study title

IMVAHA: Improving Menstrual and VAginal Health for All

Acronym: IMVAHA

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Oct 17, 2024
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.